Ephedra-free, "super-stimulant" weight-loss supplement delivers "more than five times the weight loss" of Cytodyne's ephedra-containing Xenadrine RFA-1, Zoller Labs states in April 5 release. Salt Lake City-based Basic Research affiliate began selling Zantrex-3 in February at health food outlets including GNC and online. Labeling claims include "rapid weight loss" and "extreme energy," focus on supplement's superiority to ephedra. Zantrex-3 features proprietary blend including caffeine, guarana, kola nut and green tea; an 84-count bottle retails for $42.99...
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
Kumar takes over as acting director of the Center for Biologics Evaluation and Research’s Office of Therapeutic Products days after director Nicole Verdun was ousted.
Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.
While treatments for scleroderma are in development, none are approved for the condition that is associated with high morbidity and mortality. The European Medicines Agency says guidance on how to design development programs for the disorder is needed.
